CoChat

Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy

Open access
Guillou, Julia, de Pellegars, Alice, Porcheret, Florence, Frémeaux-Bacchi, Véronique, Allain-Launay, Emma, Debord, Camille, Denis, Manon, Péréon, Yann, Barnérias, Christine, Desguerre, Isabelle, Roussey, Gwenaëlle, Mercier, Sandra · 2022 · Blood Advances

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Adeno-associated virus (AAV) gene therapies are highly promising, such as the onasemnogene abeparvovec (Zolgensma) in spinal muscle atrophy (SMA). We report the first case of fatal systemic thrombotic microangiopathy (TMA) following onasemnogene abeparvovec in a 6-month-old child with SMA type 1, carrying a potential genetic predisposition in the complement factor I gene. Other cases of TMA have recently been reported after onasemnogene abeparvovec and after AAV9 minidystrophin therapy in Duchenne muscular dystrophy. The risk-benefit ratio of this therapy must therefore be assessed. Early recognition of TMA and targeted immunotherapy are fundamental to ensure the safety of patients treated with AAV gene therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2021006419

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Clinico-biological characteristics of TMA. (A) Trends in platelet and LDH levels during hospitalization. Eculizumab was administrated at days 13, 19, and 40 after onasemnogene abeparvovec infusion. (B) Peripheral smear shows 6% schistocytes (arrows) at D12 (original magnification, ×50). (C) TMA diffuse skin damage.
Figure 1. Clinico-biological characteristics of TMA. (A) Trends in platelet and LDH levels during hospitalization. Eculizumab was administrated at days 13, 19, and 40 after onasemnogene abeparvovec infusion. (B) Peripheral smear shows 6% schistocytes (arrows) at D12 (original magnification, ×50). (C) TMA diffuse skin damage.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 166

Metadata

Authors
Guillou, J., de Pellegars, A., Porcheret, F., Frémeaux-Bacchi, V., Allain-Launay, E., Debord, C., Denis, M., Péréon, Y., Barnérias, C., Desguerre, I., Roussey, G., & Mercier, S.
Affiliations
  • Centre Hospitalier Universitaire de Nantes (FR)
  • 2CHU Angers, Fédération de Pédiatrie, Angers, France;
  • 3Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service d'Immunologie, Paris, France;
  • 1Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France;
  • Centre National de la Recherche Scientifique (FR)
  • Hôpital Necker-Enfants Malades (FR)
Corresponding author
Mercier, Sandra
Venue
Blood Advances
Published
2022-07-22
Volume
6
Issue
14
Pages
4266-4270
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W4280574529
Cited by
166
References
13
Citations by year
2026: 37 · 2025: 41 · 2024: 38 · 2023: 42 · 2022: 8
FWCI
12.32
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Keywords
thrombotic microangiopathy, onasemnogene abeparvovec, adeno-associated virus gene therapy, spinal muscular atrophy type 1, complement factor I, Duchenne muscular dystrophy, pediatric patient safety, targeted immunotherapy
MeSH terms
Dependovirus, Humans, Immunotherapy, Infant, Muscular Atrophy, Spinal, Genetic Therapy, Fatal Outcome, Thrombotic Microangiopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. https://app.cochat.ai/papers/10.1182/bloodadvances.2021006419
The paper
Guillou, J., de Pellegars, A., Porcheret, F., Frémeaux-Bacchi, V., Allain-Launay, E., Debord, C., Denis, M., Péréon, Y., Barnérias, C., Desguerre, I., Roussey, G., & Mercier, S. (2022). Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Advances. https://doi.org/10.1182/bloodadvances.2021006419

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.